Dana-Farber Cancer Institute reports in EurekAlert! that by analyzing data from hundreds of patients with asymptomatic Waldenström macroglobulinemia (AWM), they have devised a risk model for determining whether patients with AWM have a low, intermediate, or high risk of developing symptomatic Waldenström macroglobulinemia (WM), which requires chemotherapy treatment. Dana-Farber is one of the leading centers in the world for Waldenström macroglobulinemia

Waldenström macroglobulinemia is a low-grade non-Hodgkin lymphoplasmacytic lymphoma associated with overproduction of monoclonal IgM protein and is often preceded by asymptomatic conditions called IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia. When the cancer progresses to its symptomatic stage, patients usually develop symptoms of anemia, peripheral neuropathy, bleeding, and enlarged spleen and liver and other constitutional symptoms.

Lead Research/Investigator

Irene Ghobrial, MD

Source: Eurek Alert

Pin It on Pinterest